DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Sepsis - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Sepsis (196)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include sepsis. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 196   Next >>

Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24

Patient: male, weighing 121.9 kg (268.2 pounds)

Reactions: Pruritus, Unresponsive To Stimuli, Device Related Infection, Pyrexia, Candidiasis, Abscess Limb, Ventricular Extrasystoles, Metabolic Acidosis, Dyspnoea, Hypotension, Pancytopenia, Tremor, Convulsion, Respiratory Failure, Fungal Infection, Ventricular Tachycardia, Sepsis, Respiratory Arrest, Pulse Absent, Sinus Tachycardia, Hypertension, Feeling Abnormal, Cardiac Arrest, Escherichia Infection, Infusion Related Reaction

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Clolar
    Dosage: 74.4 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-19
    End date: 2012-06-23

Cyclophosphamide
    Dosage: daily for 5 days
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-19
    End date: 2012-06-23

Epinephrine
    Dosage: 4 df, unk
    Indication: Cardiac Arrest
    Start date: 2012-07-14
    End date: 2012-07-14

Epinephrine
    Dosage: unk
    Start date: 2012-07-14
    End date: 2012-07-14

Etoposide
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-06-19
    End date: 2012-06-23

Oncaspar
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-07-02
    End date: 2012-07-02

Vincristine Sulfate
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-07-02
    End date: 2012-07-02

Other drugs received by patient: Colace; Bactrim; Stomatitis Mouthwash; Prilosec; Lortab; Cymbalta; Ondansetron; Ambien



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: Confusional State, White Blood Cell Count Decreased, Sepsis, Febrile Neutropenia, Encephalopathy, Platelet Count Decreased, Cystitis, Neutrophil Count Decreased

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Blinded Vorinostat
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Cyclophosphamide
    Dosage: 750 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Doxorubicin Hydrochloride
    Dosage: 50 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Placebo
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Prednisone TAB
    Dosage: 100 mg, qd, on days 3-7
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25
    End date: 2012-07-29

Rituximab
    Dosage: 375 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Simvastatin
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Simvastatin
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Vincristine Sulfate
    Dosage: 1.4 mg, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: Confusional State, White Blood Cell Count Decreased, Sepsis, Febrile Neutropenia, Encephalopathy, Platelet Count Decreased, Cystitis, Neutrophil Count Decreased

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Blinded Vorinostat
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Cyclophosphamide
    Dosage: 750 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Doxorubicin Hydrochloride
    Dosage: 50 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Placebo
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Prednisone TAB
    Dosage: 100 mg, qd, on days 3-7
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25
    End date: 2012-07-29

Rituximab
    Dosage: 375 mg/m2, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25

Simvastatin
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Simvastatin
    Dosage: 400 mg, qd, on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-23
    End date: 2012-07-27

Vincristine Sulfate
    Dosage: 1.4 mg, once, on day 3
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-07-25



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-21

Patient: male, weighing 115.7 kg (254.5 pounds)

Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Cyclophosphamide
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Prednisone TAB
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Remicade
    Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
    Indication: Rheumatoid Arthritis
    Start date: 2001-10-01
    End date: 2006-06-29

Vincristine
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Other drugs received by patient: Azulfadine; Lisinopril



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13

Patient:

Reactions: Sepsis, Diffuse Large B-Cell Lymphoma Recurrent, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin
    Dosage: days 1 and 5
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: patients on r-chop received 750 mg/m2 on day 1; and acvbp received 1200 mg/m2
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: day 1,patients on r-chop recieved 50 mg/m2; and on acvbp received 75 mg/m2 on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: days 1 through 5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: day 1, in r-chop regimen
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: day 1 in r-chop regimen
    Indication: Diffuse Large B-Cell Lymphoma

Vindesine
    Dosage: days 1 and 5
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Fluorodeoxyglucose F 18



Possible Cyclophosphamide side effects in 73 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-10

Patient: 73 year old female

Reactions: Neutropenic Sepsis, Sepsis

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-04-26
    End date: 2012-07-26

Dexamethasone
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-04-26
    End date: 2012-07-22

Revlimid
    Dosage: 10 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-04-26
    End date: 2012-07-01



Possible Cyclophosphamide side effects in 19 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-03

Patient: 19 year old female

Reactions: Dyspnoea, Pancytopenia, Pyrexia, Chronic Myeloid Leukaemia, Multi-Organ Failure, Fatigue, Neoplasm Malignant, Sepsis, Chest Pain

Adverse event resulted in: death

Drug(s) suspected as cause:
Cisplatin
    Dosage: 8 consolidation cycles
    Indication: Medulloblastoma

Cyclophosphamide
    Dosage: 8 consolidation cycles
    Indication: Medulloblastoma

Vincristine Sulfate
    Dosage: weekly, followed by 8 consolidation cycles
    Indication: Medulloblastoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-31

Patient:

Reactions: Neutropenic Sepsis, Sepsis, Dyspraxia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: on day 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in 24 year old female

Reported by a consumer/non-health professional from United States on 2012-07-30

Patient: 24 year old female, weighing 51.0 kg (112.2 pounds)

Reactions: Abdominal Pain, Hyperkalaemia, Disseminated Intravascular Coagulation, Gastrointestinal Necrosis, Acidosis, Nephrolithiasis, Skin Discolouration, Ecchymosis, Clostridial Infection, Emphysema, White Blood Cell Count Decreased, Hypotension, Anaemia, Condition Aggravated, Soft Tissue Infection, Sepsis, Flank Pain, Colitis, Cardiac Arrest, Sinus Tachycardia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: last dose on 16jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Cytarabine
    Dosage: last dose:17jun12 route:intra ommya
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Dexamethasone
    Dosage: last dose:16jun12
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Doxorubicin HCL
    Dosage: last dose:17jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Filgrastim
    Dosage: last dose:18jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17
    End date: 2012-01-01

Leucovorin Calcium
    Dosage: last dose :21may12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Mesna
    Dosage: last dose:17jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Methotrexate
    Dosage: last dose:13jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Methylprednisolone
    Dosage: last dose:21may12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Sprycel
    Dosage: last dose on 26jun12
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17

Vincristine Sulfate
    Dosage: last dose:17jun12
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-05-17



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-27

Patient:

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride

Prednisone
    Indication: B-Cell Lymphoma

Rituximab
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in 70 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-19

Patient: 70 year old male

Reactions: Sepsis, Urinary Tract Infection

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Start date: 2012-03-14
    End date: 2012-07-06

Dexamethasone
    Dosage: 20 milligram
    Administration route: Oral
    Start date: 2012-03-14
    End date: 2012-07-06

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Start date: 2012-03-14
    End date: 2012-07-06



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17

Patient:

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Rituxan
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 300 mg/m2

Cyclophosphamide
    Dosage: 250 mg/m2, bid for six doses
    Indication: non-Hodgkin's Lymphoma

Cytarabine
    Dosage: 100 mg/m2, daily x 5 days
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: 30 mg/m2, single
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: 60 mg/m2, single

Hydrocortisone Acetate
    Dosage: given with methotrexate
    Indication: non-Hodgkin's Lymphoma

Hydrocortisone Acetate
    Dosage: given with cytarabine

Methotrexate
    Dosage: 3000 mg/m2, single

Methotrexate
    Dosage: given with hydrocortisone twice x 2
    Indication: non-Hodgkin's Lymphoma

Methotrexate
    Dosage: 1500 mg/m2, single

Prednisolone
    Dosage: 60 mg/m2, daily for 5 days then tapered over 3 days
    Indication: non-Hodgkin's Lymphoma

Prednisolone
    Dosage: 60 mg/m2, daily for 7 days

Rituximab
    Dosage: 1875 mg/m2, every 2-4 weeks for 5 total doses
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: 2 mg/m2, single

Vincristine
    Dosage: 1 mg/m2, single
    Indication: non-Hodgkin's Lymphoma



Possible Cyclophosphamide side effects in 18 month old male

Reported by a physician from United States on 2012-07-06

Patient: 18 month old male, weighing 11.4 kg (25.1 pounds)

Reactions: Sepsis, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Asparaginase
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Dexamethasone Sodium Phosphate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Dexamethasone Sodium Phosphate

Etoposide
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Lestaurtinib
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Lestaurtinib

Mercaptopurine

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Methotrexate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18

Methotrexate

Vincristine

Vincristine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-04-18



Possible Cyclophosphamide side effects in 70 year old male

Reported by a consumer/non-health professional from United Kingdom on 2012-07-05

Patient: 70 year old male

Reactions: Sepsis, Lower Respiratory Tract Infection, Influenza

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-11-30
    End date: 2011-01-05

Dexamethasone Sodium Phosphate
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-11-30
    End date: 2011-01-01

Thalidomide
    Dosage: 50 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-11-30
    End date: 2011-01-10



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: female

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 on days 1-14 oral)
    Administration route: Oral
    Indication: Breast Cancer

Fluorouracil
    Dosage: (600 mg/m2 ondays 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer

Methotrexate
    Dosage: (40 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in 37 year old female

Reported by a health professional (non-physician/pharmacist) from Turkey on 2012-06-29

Patient: 37 year old female

Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Sepsis, Acute Monocytic Leukaemia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: Breast Cancer

Azacitidine

Azacitidine

Cyclophosphamide
    Indication: Breast Cancer

Cytarabine
    Indication: Acute Monocytic Leukaemia

Cytarabine
    Indication: Acute Monocytic Leukaemia

Fludarabine Phosphate
    Indication: Acute Monocytic Leukaemia

Granulocyte Colony-Stimulating Factor
    Indication: Acute Monocytic Leukaemia

Idarubicin HCL

Idarubicin HCL
    Indication: Acute Monocytic Leukaemia



Possible Cyclophosphamide side effects in female

Reported by a physician from Germany on 2012-06-28

Patient: female

Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Neulasta
    Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Dosage: frequency 1 times in 2 week for 5 days
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole



Possible Cyclophosphamide side effects in 16 month old female

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-26

Patient: 16 month old female

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Carboplatin
    Dosage: 10 mg/kg daily on days 0
    Indication: Brain Neoplasm Malignant

Cisplatin
    Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Cyclophosphamide
    Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)

Etoposide
    Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Ifosfamide
    Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
    Indication: Brain Neoplasm Malignant

Vincristine
    Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
    Indication: Brain Neoplasm Malignant



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-06-26

Patient: female

Reactions: Syncope, Sepsis, Hypotension, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1493 m
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Neulasta
    Indication: B-Cell Lymphoma
    Start date: 2012-04-29

Prednisolone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-04-30

Rituximab
    Indication: B-Cell Lymphoma
    Start date: 2012-04-25

Vincristine
    Dosage: 3.94 m
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Other drugs received by patient: Simvastatin; Levothyroxine; Ramipril; Acyclovir; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Torsemide; Pantoprazole; Nebivolol



Possible Cyclophosphamide side effects in 16 month old female

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-06-25

Patient: 16 month old female

Reactions: Sepsis

Adverse event resulted in: death

Drug(s) suspected as cause:
Carboplatin
    Dosage: 10 mg/kg daily on days 0
    Indication: Brain Neoplasm Malignant

Cisplatin
    Dosage: 3 mg/kg, once daily on day 0 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Cyclophosphamide
    Dosage: 50 mg/kg once daily on day 1 and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily on days 0, 1, and 2 (cecv regimen)
    Indication: Brain Neoplasm Malignant

Etoposide
    Dosage: 2.5 mg/kg once daily for 5 consecutive days from day 0 (ceiv regimen)

Ifosfamide
    Dosage: 50 mg/kg daily for 5 consecutive days from day 0 (ceiv regimen)
    Indication: Brain Neoplasm Malignant

Vincristine
    Dosage: 0.05 mg/kg, 1x/day, day 0 and 7
    Indication: Brain Neoplasm Malignant



Possible Cyclophosphamide side effects in 37 year old female

Reported by a physician from Turkey on 2012-06-22

Patient: 37 year old female

Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Acute Myeloid Leukaemia, Sepsis, Febrile Neutropenia, Acute Monocytic Leukaemia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 200 mg/m2 on days 3-6, every 28 days, for 4 cycles
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 40 mg/m2 on day 1, every 28 days, for 4 cycles
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in 67 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-06-22

Patient: 67 year old male

Reactions: Sepsis, Pulmonary Oedema, Pyrexia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-30

Dexamethasone
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-30

Thalidomide
    Dosage: 50 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-30



Possible Cyclophosphamide side effects in

Reported by a consumer/non-health professional from Germany on 2012-06-21

Patient:

Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous

Adverse event resulted in: death

Drug(s) suspected as cause:
Busulfan
    Dosage: 12 mg/kg, unk
    Indication: Product Used FOR Unknown Indication

Carboplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cisplatin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: 2000 mg/m2, unk
    Indication: Product Used FOR Unknown Indication

Doxorubicin Hydrochloride
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Etoposide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Fludara
    Dosage: 250 mg/m2, unk
    Indication: Product Used FOR Unknown Indication

Ifosfamide
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Neupogen
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Rituxan
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Vincristine Sulfate
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Zevalin
    Dosage: unk
    Indication: Product Used FOR Unknown Indication



Possible Cyclophosphamide side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Methotrexate
    Dosage: 3000 mg/m2; administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Methotrexate
    Dosage: as part of copadm2 and cym1

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm1

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III



Possible Cyclophosphamide side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Methotrexate
    Dosage: as part of copadm2 and cym1

Methotrexate
    Dosage: administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm1



Possible Cyclophosphamide side effects in 10 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21

Patient: 10 year old female

Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2

Cyclophosphamide
    Dosage: 300 mg/m2 as part of cop
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: continuous infusion of 100 mg/m2 daily for 5 days
    Indication: Burkitt's Lymphoma Stage III

Cytarabine
    Dosage: administered once with hydrocortisone as part of cym1

Doxorubicin HCL
    Dosage: as part of copadm1
    Indication: Burkitt's Lymphoma Stage III

Doxorubicin HCL
    Dosage: as part of copadm2

Hydrocortisone
    Dosage: administered once with cytarabine as part of cym1

Hydrocortisone
    Dosage: administered with methotrexate
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm2 and cym1

Methotrexate
    Dosage: administered with hydrocortisone
    Indication: Burkitt's Lymphoma Stage III

Methotrexate
    Dosage: as part of copadm1

Prednisolone
    Dosage: 60 mg/m2/day for 7 days as part of cop
    Indication: Burkitt's Lymphoma Stage III

Prednisolone
    Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2

Rituximab
    Dosage: five total doses; cumulative dose of 1875 mg/m2
    Indication: Burkitt's Lymphoma Stage III

Vincristine
    Dosage: as part of copadm2

Vincristine
    Dosage: as part of copadm1

Vincristine
    Dosage: as part of cop
    Indication: Burkitt's Lymphoma Stage III



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014